Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Janet L. Anderl"'
Autor:
Tony Muchamuel, R. Andrea Fan, Janet L. Anderl, Darrin J. Bomba, Henry W. B. Johnson, Eric Lowe, Brian B. Tuch, Dustin L. McMinn, Beatriz Millare, Christopher J. Kirk
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders. Here, we characterized KZR-616 in vitro and in vivo using multiplexed cytokine analysis, lymphocyte activatio
Externí odkaz:
https://doaj.org/article/b8472904a1e148a78a2945fec4d80181
Autor:
Shahid Rehan, Dale Tranter, Phillip P. Sharp, Eric Lowe, Janet L. Anderl, Tony Muchamuel, Vahid Abrishami, Suvi Kuivanen, Nicole Wenzell, Andy Jennings, Chakrapani Kalyanaraman, Gregory B. Craven, Tomas Strandin, Matti Javanainen, Olli Vapalahti, Matt Jacobson, Dustin McMinn, Christopher J. Kirk, Juha T. Huiskonen, Jack Taunton, Ville O. Paavilainen
Publikováno v:
Nature Chemical Biology.
Preventing the biogenesis of disease-relevant proteins is an attractive therapeutic strategy, but attempts to target essential protein biogenesis factors have been hampered by excessive toxicity. Here we describe KZR-8445, a cyclic depsipeptide that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3d80e4c56784d2bb4cb97a4236159d8
https://doi.org/10.1038/s41589-023-01326-1
https://doi.org/10.1038/s41589-023-01326-1
Autor:
Christopher J. Kirk, Andrew J. Ball, Christoph Driessen, Mark K. Bennett, Tony Muchamuel, Susan J. Lee, Kevin D. Shenk, Francesco Parlati, Marianne Kraus, Janet L. Anderl, Shirin Arastu-Kapur
Supplementary Figures S1-S4; Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e20c3ba1cf4d484b2bffd0c91ffc79d
https://doi.org/10.1158/1078-0432.22442163.v1
https://doi.org/10.1158/1078-0432.22442163.v1
Autor:
Christopher J. Kirk, Andrew J. Ball, Christoph Driessen, Mark K. Bennett, Tony Muchamuel, Susan J. Lee, Kevin D. Shenk, Francesco Parlati, Marianne Kraus, Janet L. Anderl, Shirin Arastu-Kapur
Purpose: Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a treatment-emergent, painful peripheral neuropathy (PN) in more than 30% of patients. Carfilzomib,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0675242182dc136a28da04501a408a42
https://doi.org/10.1158/1078-0432.c.6518973
https://doi.org/10.1158/1078-0432.c.6518973
Autor:
Bruce D. Hammock, Christophe Morisseau, Tony Muchamuel, Janet L. Anderl, Henry Johnson, Dustin McMinn, Ying Fang, Christopher J. Kirk, Jinhai Wang
Publikováno v:
Drug Metabolism and Disposition. 49:810-821
KZR-616 is an irreversible tripeptide epoxyketone-based selective inhibitor of the human immunoproteasome. Inhibition of the immunoproteasome results in anti-inflammatory activity in vitro and, based on promising therapeutic activity in animal models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d2d7bf887c79ec6526156696fadfdbe
https://doi.org/10.1124/dmd.120.000307
https://doi.org/10.1124/dmd.120.000307
Autor:
Michael B Winter, Florencia La Greca, Shirin Arastu-Kapur, Francesco Caiazza, Peter Cimermancic, Tonia J Buchholz, Janet L Anderl, Matthew Ravalin, Markus F Bohn, Andrej Sali, Anthony J O'Donoghue, Charles S Craik
Publikováno v:
eLife, Vol 6 (2017)
The immunoproteasome (iP) has been proposed to perform specialized roles in MHC class I antigen presentation, cytokine modulation, and T cell differentiation and has emerged as a promising therapeutic target for autoimmune disorders and cancer. Howev
Externí odkaz:
https://doaj.org/article/e24818c8dbee416fbc11f00f86293fde
Autor:
Tony Muchamuel, Andrea R. Fan, Dustin McMinn, Simeon Bowers, Christopher J. Kirk, Henry Johnson, Janet L. Anderl, David C. Moebius, Eric Lowe
Publikováno v:
Journal of Medicinal Chemistry. 61:11127-11143
Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low mole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e3c93b47a1faa5b8f7697f4892f7714
https://doi.org/10.1021/acs.jmedchem.8b01201
https://doi.org/10.1021/acs.jmedchem.8b01201
Autor:
Yu Qian, Jennifer A. Whang, Eric Lowe, Tony Muchamuel, Beatriz Millare, Henry Johnson, Janet L. Anderl, Jinhai Wang, Dustin McMinn, Christopher J. Kirk
Publikováno v:
Cancer Research. 81:323-323
Secreted and transmembrane (TM) proteins play key roles in malignant transformation and tumor growth. During translation, the majority of these proteins require translocation through the Sec61 protein complex into the endoplasmic reticulum (ER) for f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e7dd7fe1d4a2a15f4f9531e6039ef0f
https://doi.org/10.1158/1538-7445.am2021-323
https://doi.org/10.1158/1538-7445.am2021-323
Autor:
Erin Bradley, Lisa M. Kelly, Janet L. Anderl, Eric Lowe, David C. Moebius, Jeffrey Jones, Shirin Arastu-Kapur, Christopher J. Kirk, Henry W. B. Johnson, John Bui, Zhengping Wang, Dustin McMinn, Tony Muchamuel
Publikováno v:
ACS Medicinal Chemistry Letters. 8:413-417
Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the design of a next generation of inhibitors targeting specific subunits within the immunoproteasome is of interest for the treatment of autoimmune disease. There are thre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6baf150fa245ff729c9b833768c2ac19
https://doi.org/10.1021/acsmedchemlett.6b00496
https://doi.org/10.1021/acsmedchemlett.6b00496
Autor:
Darrin Bomba, Janet L. Anderl, Maria Dall'Era, Niti Goel, Richard Furie, Jinhai Wang, Christopher J. Kirk, Massiel Prieto
Publikováno v:
Poster Presentations.
Background Nonspecific proteasome inhibitors, e.g., bortezomib (BTZ), target both the constitutive and immuno- proteasomes and are standard of care for multiple myeloma. While BTZ has been used to treat refractory systemic lupus erythematosus (SLE) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbc37465e7ec65d46941187f73ec10ab
https://doi.org/10.1136/annrheumdis-2019-eular.1955
https://doi.org/10.1136/annrheumdis-2019-eular.1955